Genomic Vision (Paris:GV) a French molecular diagnostics company
specializing in the development of diagnostic tests for genetic diseases
and cancers based on molecular combing technology, announces that
Company management will participate at the Canaccord Genuity 2015
Medical Technology & Diagnostics Forum taking place on November 19th
at the Westin Grand Central Hotel in New York City. Aaron Bensimon,
Ph.D., CEO & President of Genomic Vision, will deliver the Company’s
corporate presentation on Thursday, November 19th at 11:40
a.m. Eastern Time (5:40 p.m. CET).

The Company’s presentation will be webcast live on the internet and can
be accessed by visiting the Investor Relations section of the Company’s
website at www.genomicvision.com.
A replay of the webcast will be archived on the Genomic Vision website
for 90 days following the presentation.

ABOUT GENOMIC VISIONFounded in 2004, Genomic Vision is a
molecular diagnostics company specialized in the development of
diagnostic tests for genetic diseases and cancers based on molecular
combing. Using this innovative technology that allows the direct
visualization of individual DNA molecules, Genomic Vision detects
quantitative and qualitative variations in the genome that are at the
origin of numerous serious pathologies. The Company is developing a
solid portfolio of tests that notably target breast cancer and cancer of
the colon. Since 2013, the Company has marketed the CombHeliX FSHD test
for identifying a myopathy that is difficult to detect,
Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a
strategic alliance with Quest Diagnostics, the American leader in
diagnostic laboratory tests, and in France. Genomic Vision has been
listed on Compartment C of Euronext Paris since April 2014.